CID/JID/OFID Manuscript Review Program
The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.
The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.
To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.
You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.
Accreditation Statement
The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.
Objectives
Through the manuscript peer review process for CID, JID, or OFID, you should be able to:
- integrate new discoveries or observations in infectious disease research that can be applied in your work
- use information resources that improve your ability to treat patients or to conduct research in infectious diseases
- identify articles that provide relevant, new data about infectious diseases that could result in additional knowledge
- apply new information that could result in improved healthcare outcomes
Disclosure Information
In compliance with ACCME’s Standards for Commercial Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID, JID and OFID, identifies and resolves all conflicts of interest prior to manuscript reviews.
CID Editors Disclosures
Editor-in-Chief
Robert T. Schooley: Advisory/Consultant: VIR; Stocks/Bonds: Antiva Biosciences; Advisory/Consultant; Stocks/Bonds: CytoDyn; Scientific Advisory Board: Monogram Biosciences, Gilead Sciences.
Deputy Editor
Ferric C. Fang: Advisory/Consultant/Honoraria: BioFire, Cepheid; Advisory/Consultant: ELITech; Supplies for Research Project: Luminex; Research Grant: Cepheid.
Assistant Deputy Editor
Barbara D. Alexander: Advisory/Consultant: Scynexis, Lediant, Cidara, Astellas; Research Grants: Shire, Gilead, Scynexis, Astellas.
Associate Editors
Constance A. Benson: Advisory/Consultant: GlaxoSmithKline, MBio Diagnostics; Research Grant: Gilead Sciences.
Carlos del Rio: Advisory/Consultant: ViiV Healthcare.
Kathryn N. Edwards: Nothing to disclose.
Vance Fowler: Advisory/Consultant/Honoraria: Bayer, Contrafect, Janssen, xBiotech, Arsanis, Moderna, Genentech, Basilea; Polyphor; Cidara, Grant Downing; Actavis; Royalties: Up-to-Date; Advisory/Consultant: Basilea, Debiopharm; Research Grants: Karius / MedImmune, Allergan/Contrafect, Genentech/Basilea; Committee Chair: Novartis.
David N. Fredricks: Patent/copyright/license: BD.
Barbara E. Murray: Advisory/Consultant/Honoraria: Back Bay Life Science Adv; Decibio; Biostrategies Group, Decile.Ten Communications (Cempra Pharmaceuticals), Paratek; Research Grants: Forest/Actavis; Cubist/Merck; Theravance; Royalties: UpToDate, ASM
Peter G. Pappas: Advisory/Consultant: Cidara, Vical, Scynexis; Mayne Pharmaceuticals; Research Grants: Astellas, IMMY, Cidara, Merck
Robin Patel: Advisory/Consultant: Curetis, Qvella, St. Jude, Beckman Coulter; Morgan Stanley; Heraeus Medical GmbH; CORMATRIX; Specific Technologies; Diaxonit; Selux Dx; GenMarkDiagnostics; LBT Innovations; PathoQuest; Genentech; DSMB: Actelion; Royalties: UpToDate; IDBR Course; Research Grants: CD Diagnostics, BioFire, Curetis, Merck, Huchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, Medicines Company
David L. Paterson: Advisory/Consultant/Honoraria: Merck, Pfizer, Achaogen, GlaxoSmithKline; Advisory Role: Shionogi; Research Grant: Merck
David A. Pegues: Advisory/Consultant: DaVita/Total Renal Care; Chair, Data Safety Monitoring Board: Seres Pharmaceutical
William A. Petri, Jr: Advisory/Consultant: Perrigo Nutritionals; TechLab
Stephanie N. Taylor; Advisory/Consultant: GlaxoSmithKline; Research Grants: Hologic, GlaxoSmithKline, Becton-Dickinson
David L. Thomas: Advisory/Consultant: Merck; Royalties: Up-to-Date Associate Statistical Editor.
Victor de Gruttola: Advisory/Consultant: Biogen, Baylor, BMS, Daiichi Sankyo, Dynavax, Genocea, Gilead, GSK, Lilly, Merck, Novo Norodisk, Prolong Pharma, Roche, ViiV
JID Editors Conflict of Interest Disclosures
Editor-in-Chief
Martin Hirsch: Nothing to disclose
Deputy Editor
David Hooper: Consultant: Macrolide Pharmaceuticals, Shionogi, Melinta Therapeutics, Selux Diagnostics, Bacterioscan, Cepheid
Associate Editors
Ann Arvin: Nothing to disclose
Marcel Behr: Nothing to disclose
Raymond Chung: Research Grants: Gilead, BMS, Janssen, Abbvie, Merck, Boehringer Ingelheim; Other: Alnylam
Peter Densen: Personal Fees: Achillion, Ionis
Joseph Kovacs: Personal Fees: Healthcare Infection Society; Non-financial support: Merck; Other: Matinas, Inc; Patent related to Pneumocystis and IL-2 in HIV infection with royalties paid
Daniel Kuritzkes: Personal Fees: Abivax, Bionor, Bristol-Myers Squibb, CytoDyn, GlaxoSmithKline, ViroStatics, InnaVirVax, Teva, Seres, Roche, Oncolys, United Bio-Pharma; Research grants and personal fees: Gilead, Merck, ViiV, Research grants: Janssen, Palisades Therapeutics
Stuart Levitz: Nothing to disclose
William Schaffner: Personal Fees: Merck, Pfizer, Dynavax, Seqirus, SutroVax, Shionogi
Jane Schwebke, Research Grants and Personal Fees: Hologic, Symbiomix, Scynexis, Toltec Pharmaceuticals, StarPharma; Research grants: BD Diagnostics, Curatek, Viamet, Gage Pharmaceuticals
Frederick Southwick: Nothing to disclose
Peter Weller: Nothing to disclose
Richard Whitley: Personal Fees: Merck, Glaxo Smith Kline, George Washington University CME Department, American Academy of Pediatrics-South Carolina Chapter; Other: Gilead Sciences, Inc., Kite-A Gilead Company
Statistical Editors
Daniel Caffrey: Nothing to disclose
Michael Hughes: Nothing to disclose
Sarah Walker: Nothing to disclose
OFID (Open Forum Infectious Diseases) Editors Conflict of Interest Disclosures
Editor-in-Chief
Paul Sax: Advisory/Consultant: AbbVie, Gilead; GSK/ViiV; Janssen; Merck
Associate Editors
Jonathan Blum: Nothing to disclose
Johanna Daily: Did not disclose
Kimberly Hanson: Nothing to disclose
Keith Kaye: Advisory/Consultant/Honoraria: Allergan, Bayer, Melinta, Nabriva, Paratek, Shinogi
Merck, Zavante, Xellia; Research Grant: Merck
Jonathan Li: Advisory/Consultant: Merck, Gilead, United Biopharma
Maunank Shah: Patent: Emocha Mobile Health; Advisory/Consultant: Gilead; Research Grant: ViiV Health Care
Abigail Zuger: Nothing to disclose